Hjem › Eggstokkreft › California › San Francisco
Kliniske studier for Eggstokkreft i San Francisco, CA
19 studier for Eggstokkreft søker deltakere på steder i og rundt San Francisco (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RekruttererFase 2
- California Pacific Medical Center - Van Ness Campus /ID# 275329, San Francisco
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RekruttererFase 3
- UCSF Medical Center at Mission Bay ( Site 0013), San Francisco
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RekruttererFase 1/2
- Research Site, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
Rekrutterer
- Kaiser Permanente-San Francisco, San Francisco
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RekruttererFase 1
- University of California, San Francisco
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruttererFase 1/2
- UCSF Medical Center-Mission Bay, San Francisco
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
RekruttererFase 3
- Site 0115, San Francisco
A Study of DM002 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- University of California San Francisco Cancer Center, San Francisco
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RekruttererFase 3
- California Pacific Medical Center-Pacific Campus, San Francisco
- Kaiser Permanente-San Francisco, San Francisco
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Rekrutterer
- Kaiser Permanente-San Francisco, San Francisco
- UCSF Medical Center-Mission Bay, San Francisco
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RekruttererFase 2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RekruttererFase 2
- 014, San Francisco
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RekruttererFase 2
- University of California San Francisco, San Francisco
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- UCSF Medical Center at Mission Bay, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Rekrutterer
- Zuckerberg San Francisco General, San Francisco
- Kaiser Foundation Research Institute, San Francisco
- University of San Francisco, San Francisco
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RekruttererFase 1
- University of California San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, San Francisco
Eggstokkreft-studier i andre byer
- Houston, TX89 studier
- New York City, NY70 studier
- Boston, MA61 studier
- Los Angeles, CA50 studier
- Nashville, TN49 studier
- Arlington, VA46 studier
- Philadelphia, PA45 studier
- Columbus, OH39 studier
- St. Louis, MO38 studier
- Chicago, IL36 studier
- Pittsburgh, PA31 studier
- San Antonio, TX31 studier
Andre studier i San Francisco
- Prostatakreft45 studier
- Brystkreft43 studier
- Ikke-småcellet lungekreft36 studier
- Kreft (alle typer)35 studier
- Hjertesvikt29 studier
- Metastatisk kreft28 studier
- Melanom22 studier
- Lungekreft22 studier
- Pankreaskreft20 studier
- Kardiovaskulær sykdom18 studier
- Kolorektal kreft18 studier
- Glioblastom17 studier
Fra ClinicalTrials.gov, data hentet 7. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.